ethyl-6-chloro-2,5-dimethylpyrimidine-4-carboxylate | 76498-32-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: ethyl-6-chloro-2,5-dimethylpyrimidine-4-carboxylate
• 英文别名: Ethyl 6-chloro-2,5-dimethylpyrimidine-4-carboxylate
• CAS: 76498-32-3
• 化学式: C₉H₁₁ClN₂O₂
• 分子量: 214.652
• InChiKey: PFJNNQORFKVGNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  ethyl-6-chloro-2,5-dimethylpyrimidine-4-carboxylate 在 palladium on activated charcoal sodium azide 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、202.65 kPa 条件下， 反应 28.0h， 生成 Ethyl 4-Amino-2,5-dimethylpyrimidine-6-carboxylate
  参考文献：
  名称：

  Chemistry of 2-substituted pyrimidines. Studies directed toward the synthesis of the pyrimidine moiety of bleomycin

  摘要：

  DOI：

  10.1021/jo00320a037
• 作为产物：
  描述：

  草酰丙酸二乙酯 在 sodium ethanolate 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 生成 ethyl-6-chloro-2,5-dimethylpyrimidine-4-carboxylate
  参考文献：
  名称：

  Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor

  摘要：

  A series of benzoylpyrimidines derived from the anilinepyrimidine CRF1 antagonists were synthesized. Several synthetic routes were developed to explore the SAR of this series of compounds. Compounds such as 8d (K-i = 15 nM) exhibited high binding affinities at the human CRF1 receptor. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.072

文献信息

• [EN] NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] NOUVEAUX ANTAGONISTES DU RÉCEPTEUR CCR2 ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011073154A1

  公开（公告）日：2011-06-23

  The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of Formula (I) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

  本发明涉及一种新型CCR2（CC趋化因子受体2）拮抗剂的化学式（I），以及它们用于提供治疗疾病和病症的药物，特别是肺部疾病如哮喘和慢性阻塞性肺病。
• NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Ebel Heiner

  公开号：US20120004252A1

  公开（公告）日：2012-01-05

  The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

  本发明涉及用于治疗疾病和疾病的新型CCR2（CC趋化因子受体2）拮抗剂及其用途，特别是用于治疗哮喘和慢性阻塞性肺病等肺部疾病的药物。
• [EN] CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD<br/>[FR] PYRIMIDINE-4 CARBOXAMIDES CYCLIQUES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR CCR2 POUR LE TRAITEMENT D'INFLAMMATIONS, DE L'ASTHME ET DES BRONCHO-PNEUMOPATHIES CHRONIQUES OBSTRUCTIVES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010070032A1

  公开（公告）日：2010-06-24

  The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. Formula (I), wherein A is selected from among a single bond, =CH-, -CH2-, -O-, -S-, and -NH-; wherein n is 1, 2 or 3; wherein Z is C or N, the other variables are as defined in the claims, as well as in form of their acid addition salts with pharmacologically acceptable acids.

  本发明涉及用于治疗疾病和疾病的新型CCR2（CC趋化因子受体2）拮抗剂及其用途，特别是用于治疗肺部疾病如哮喘和慢性阻塞性肺病的药物。公式（I），其中A从单键，=CH-，-CH2-，-O-，-S-和-NH-中选择；其中n为1、2或3；其中Z为C或N，其他变量如声明中所定义，以及以药理学上可接受的酸的酸盐形式存在。
• [EN] NEW SELECTIVE CCR2 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES SÉLECTIFS DE CCR2
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012171863A1

  公开（公告）日：2012-12-20

  The present invention relates to novel and selective antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD as well as pain.

  本发明涉及用于治疗疾病和病症的新型选择性CCR2（CC化学因子受体2）拮抗剂，尤其是用于治疗哮喘和慢性阻塞性肺病（COPD）以及疼痛的药物。
• NEW SELECTIVE CCR2 ANTAGONISTS
  申请人：EBEL Heiner

  公开号：US20130150354A1

  公开（公告）日：2013-06-13

  The present invention relates to novel and selective antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD as well as pain.

  本发明涉及新颖和选择性的CCR2（CC趋化因子受体2）拮抗剂，以及它们用于提供治疗疾病和病症的药物，特别是治疗哮喘、慢性阻塞性肺疾病（COPD）以及疼痛的药物。